Reach Us +44-7482878454
Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa | OMICS International | Abstract
ISSN 2155-6113

Journal of AIDS & Clinical Research
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa

Nimzing G Ladep1*, Oche O Agbaji2, Patricia A Agaba2,3, Auwal Muazu2, Placid Ugoagwu2, Godwin Imade2, Graham S Cooke1, Livia Vivas4, Sheena Mc Cormack4, Simon D Taylor-Robinson1, John Idoko2,5 and Phyllis Kanki6

1Hepatology Unit, Department of Medicine, Imperial College London, St Mary’s Hospital Campus, South Wharf Road, London W2 1NY, United Kingdom

2AIDS Prevention Initiative in Nigeria & Jos University Teaching Hospital, 2 Murtala Mohammed Way, PMB 2076, Jos, Plateau State, Nigeria

3Department of Family Medicine, University of Jos, Plateau State, Nigeria

4Medical Research Council Clinical Trials Unit, Aviation House, 125 Kingsway, London, WC2B 6NH, United Kingdom

5National Agency for the Control of AIDS, Plot 823, Ralph Sodeinde Street, CBD, Abuja, Nigeria

6HarvardSchool of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA

*Corresponding Author:
Nimzing G Ladep
Hepatology Unit, Imperial College London, St Mary’s Hospital Campus
10th Floor QEQM Building, South Wharf Road, W2 1NY, London, UK
Tel: +44 (0)203 312 6454
Fax: +44 (0)207 724 9369
E-mail: [email protected]

Received Date: June 02, 2013; Accepted Date: June 21, 2013; Published Date: June 29, 2013

Citation: Ladep NG, Agbaji OO, Agaba PA, Muazu A, Ugoagwu P, et al (2013) Hepatitis B Co-Infection is Associated with Poorer Survival of HIV-Infected Patients on Highly Active Antiretroviral Therapy in West Africa. J AIDS Clinic Res S3:006. doi:10.4172/2155-6113.S3-006

Copyright: © 2013 Ladep NG, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Background: Hepatitis B has been reported to be high in HIV-infected African populations. However, the impact of this co-infection on the survival of HIV-infected Africans on long-term highly active antiretroviral therapy (HAART) remains poorly characterised. We investigated the impact of HBV/HIV co-infection on survival of HIV infected patients undergoing antiretroviral therapy in a West African population.

Methods: This was a clinic-based cohort study of HIV-infected adults enrolled in Nigeria, West Africa. Study subjects (9,758) were screened for hepatitis B and hepatitis C at HAART initiation. Kaplan-Meier survival and Cox proportional hazards models were used to estimate probability of survivaland toidentify predictors of mortality respectively, based on hepatitis B surface antigen status. All patients had signed an informed written consent before enrolment into the study; and we additionally obtained permission for secondary use of data from the Harvard institutional review board.

Results: Patients were followed up for a median of 41 months (interquartile range: 30-62 months) during which, 181 (1.9%) patients died. Most of the deaths; 143 (79.0%) occurred prior to availability of Tenofovir. Among those that were on antiretroviral therapy, hepatitis B co-infected patients experienced a significantly lower survival than HIV mono-infected patients at 74 months of follow up (94% vs. 97%; p=0.0097). Generally, hepatitis B co-infection: HBsAg-positive/HIV-positive (Hazards Rate [HR]; 1.5: 95% CI 1.09-2.11), co-morbid tuberculosis (HR; 2.2: 95% CI 1.57-2.96) and male gender (HR; 1.5: 95% CI 1.08-2.00) were significantly predictive of mortality. Categorising the patients based on use of Tenofovir, HBV infection failed to become a predictor of mortality among those on Tenofovircontaining HAART.

Conclusions: HBsAg-positive status was associated with reduced survival and was an independent predictor of mortality in this African HIV cohort on HAART. However, Tenofovir annulled the impact of HBV on mortality of HIV patients in the present study cohort.